Skip to content

Exercise During the Allogeneic Stem Cell Transplantation

Exercise During the Allogeneic Stem Cell Transplantation

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00883714
Enrollment
60
Registered
2009-04-20
Start date
2009-05-31
Completion date
2011-08-31
Last updated
2009-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic Stem Cell Transplantation, Fatigue

Keywords

Exercise, sport, Allogeneic blood stem cell transplantation, Blood stem cell transplantation, Fatigue, Cancer, Physical performance, Mood, Complications

Brief summary

The study will evaluate the effects of a structured endurance exercise program on the physical performance, the mood and the complications of patients with hematological malignancies undergoing a high-dose chemotherapy followed by an allogeneic peripheral blood stem cell transplantation.

Interventions

OTHERSupervised exercise

The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.

OTHERExercise Instruction

The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Neoplastic malignancy * Allogeneic peripheral stem cell transplantation * Proficiency in German

Exclusion criteria

* Cardiorespiratory, metabolical, osteoarticular or immunological disorders which can be aggravated by exercise * Pathological stress-ECG at admission

Design outcomes

Primary

MeasureTime frame
VO2maxAt recruitment and after 4 weeks

Secondary

MeasureTime frame
Complications4 weeks
MoodAt recruitment and after 4 weeks
Requirement for blood and platelets transfusions4 weeks

Countries

Germany

Contacts

Primary ContactFernando Dimeo, MD
fernando.dimeo@charite.de+493084452098

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026